Merrimack CEO is out as the biotech restructures, chopping its workforce and overhauling R&D
Merrimack Pharmaceuticals $MACK is cutting back and refocusing its research efforts in a major overhaul, which includes the departure of longtime CEO Bob Mulroy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
